Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial

INTRODUCTION: Antiviral drugs have shown limited effectiveness in treating patients with coronavirus disease 2019 (COVID-19). We aimed to assess the effects of a favipiravir and hydroxychloroquine combination on treating moderate-to-severe COVID-19 patients. METHODS: An investigator-initiated, multi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Infect Dis Ther
Main Authors: Bosaeed, Mohammad, Mahmoud, Ebrahim, Alharbi, Ahmad, Altayib, Hadeel, Albayat, Hawra, Alharbi, Faisal, Ghalilah, Khalid, Al Arfaj, Abdulmajid, AlJishi, Jumana, Alarfaj, Abdullatif, Alqahtani, Hajar, Almutairi, Badriah M., Almaghaslah, Manar, Alyahya, Nawaf M., Bawazir, Abdullah, AlEisa, Saud, Alsaedy, Abdulrahman, Bouchama, Abderrezak, Alharbi, Malak, AlShamrani, Majid, Al Johani, Sameera, Aljeraisy, Majed, Alzahrani, Mohammed, Althaqafi, Abdulhakeem O., Almarhabi, Hassan, Alotaibi, Athari, Alqahtani, Nasser, Arabi, Yaseen M., Aldibasi, Omar S., Alaskar, Ahmad
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Healthcare 2021
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8316887/
https://ncbi.nlm.nih.gov/pubmed/34319552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40121-021-00496-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados